Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor. It was developed by MedImmune for the treatment of asthma. It is currently marketed by Astrazeneca.
Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016. From Wikipedia
